Connect Biopharma reports positive early data for rademikibart in asthma study
Connect Biopharma announced positive preliminary data from a global Phase 2 study of its asthma drug rademikibart, showing a 66% reduction in treatment failures at 28 days and significant lung function improvements.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day